Li Gan, senior author (Cornell University)
A potential target for Alzheimer's treatment? Researchers unearth new immune response pathway
Most Alzheimer’s drugs, including Biogen’s aducanumab (Aduhelm) and Eli Lilly’s donanemab, target amyloid plaques, misfolded protein clumps that build up in the brain, which are …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
